HSDT vs. NDRA, NUWE, PHIO, PHAS, SXTP, SEEL, VIRI, ZVSA, CYCC, and IONM
Should you be buying Helius Medical Technologies stock or one of its competitors? The main competitors of Helius Medical Technologies include ENDRA Life Sciences (NDRA), Nuwellis (NUWE), Phio Pharmaceuticals (PHIO), PhaseBio Pharmaceuticals (PHAS), 60 Degrees Pharmaceuticals (SXTP), Seelos Therapeutics (SEEL), Virios Therapeutics (VIRI), ZyVersa Therapeutics (ZVSA), Cyclacel Pharmaceuticals (CYCC), and Assure (IONM). These companies are all part of the "medical" sector.
Helius Medical Technologies (NASDAQ:HSDT) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, community ranking, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.
18.6% of Helius Medical Technologies shares are held by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are held by institutional investors. 7.3% of Helius Medical Technologies shares are held by company insiders. Comparatively, 4.8% of ENDRA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
ENDRA Life Sciences received 215 more outperform votes than Helius Medical Technologies when rated by MarketBeat users. Likewise, 62.67% of users gave ENDRA Life Sciences an outperform vote while only 57.14% of users gave Helius Medical Technologies an outperform vote.
In the previous week, Helius Medical Technologies had 1 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 5 mentions for Helius Medical Technologies and 4 mentions for ENDRA Life Sciences. Helius Medical Technologies' average media sentiment score of 0.88 beat ENDRA Life Sciences' score of 0.34 indicating that Helius Medical Technologies is being referred to more favorably in the media.
Helius Medical Technologies presently has a consensus price target of $24.00, indicating a potential upside of 1,867.21%. Given Helius Medical Technologies' higher possible upside, equities research analysts plainly believe Helius Medical Technologies is more favorable than ENDRA Life Sciences.
ENDRA Life Sciences has a net margin of 0.00% compared to Helius Medical Technologies' net margin of -1,328.14%. ENDRA Life Sciences' return on equity of -204.78% beat Helius Medical Technologies' return on equity.
Helius Medical Technologies has higher revenue and earnings than ENDRA Life Sciences. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Helius Medical Technologies, indicating that it is currently the more affordable of the two stocks.
Helius Medical Technologies has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.
Summary
Helius Medical Technologies beats ENDRA Life Sciences on 11 of the 16 factors compared between the two stocks.
Get Helius Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSDT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HSDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Helius Medical Technologies Competitors List
Related Companies and Tools
